Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials

By afschroeder • June 8, 2025

Cabanski CR, Yang E, Stewart MD, Allen JD, Connolly JE, Dugan U, Greenberg PD, Mackall CL, June CH, Marson A, Maus MV, Ribas A. Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials. J Immunother Cancer. 2025 Jun 5;13(6):e011301. doi: 10.1136/jitc-2024-011301. PMID: 40480658; PMCID: PMC12142127.

Tags: Adoptive cell therapy - ACT, Chimeric antigen receptor - CAR, Gene therapy, Hematology/Oncology, Publications, Solid tumor, T cell Receptor - TCR

Finetuning Type I Interferon Signaling to Enhance T Cell Immunity in HIV Infection

Mu W, Kedia N, Zhen A. Finetuning Type I Interferon Signaling to Enhance T Cell Immunity in HIV Infection. Viruses. 2025 May 29;17(6):774. doi: 10.3390/v17060774.[...]

NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer

Braunstein LZ, Mitchell MP, Bandos H, Sikov WM, Khan AJ, Chen PY, Ganz PA, Jagsi R, White JR, Cecchini RS, Kang H, Puhalla SL, Bolton[...]

Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer

Moghanaki D, Cameron EA, Garon EB. Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer. Lung Cancer. 2025 Jun[...]